Bayer, which acquired the weedkiller as part of its purchase of
Monsanto last year, was initially scheduled to face its first trial
outside California in St. Louis, Missouri, on Aug. 19, brought by
Illinois resident Sharlean Gordon, who blames her non-Hodgkin's
lymphoma on using Roundup at home.
"We anticipate that this court case will be postponed but we have
not received any written decision," a Bayer spokesman said. He would
not comment on how Bayer was informed of the delay or on the reason
German weekly Wirtschaftswoche earlier reported the likely delay.
Bayer has seen its market value slashed by about 30 billion euros
since August last year, when a California jury in the first such
lawsuit found that Monsanto should have warned of the alleged cancer
[to top of second column]
The company, which says regulators and extensive research have found
glyphosate to be safe, is banking on U.S. appeals courts to reverse
or tone down the first three court rulings that have so far awarded
tens of millions of dollars to each plaintiff.
Bayer has previously flagged two more St. Louis cases due to start
in September and October, respectively, but the spokesman on
Wednesday said he could not comment on their timing.
(Reporting by Ludwig Burger and Patricia Weiss; editing by David
[© 2019 Thomson Reuters. All rights
Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.